Ultragenyx Pharmaceutical (NASDAQ:RARE) Sees Unusually-High Trading Volume – Should You Buy?

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) saw unusually-high trading volume on Tuesday . Approximately 1,460,379 shares changed hands during mid-day trading, a decline of 30% from the previous session’s volume of 2,086,481 shares.The stock last traded at $24.7430 and had previously closed at $25.38.

Analysts Set New Price Targets

Several brokerages have recently weighed in on RARE. Weiss Ratings upgraded shares of Ultragenyx Pharmaceutical from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, May 8th. Truist Financial raised shares of Ultragenyx Pharmaceutical to a “strong-buy” rating in a report on Wednesday, March 25th. Guggenheim dropped their price objective on shares of Ultragenyx Pharmaceutical from $52.00 to $43.00 and set a “buy” rating for the company in a research note on Friday, May 8th. Cantor Fitzgerald raised their target price on shares of Ultragenyx Pharmaceutical from $84.00 to $96.00 and gave the stock an “overweight” rating in a research report on Thursday, May 21st. Finally, JPMorgan Chase & Co. decreased their target price on shares of Ultragenyx Pharmaceutical from $120.00 to $74.00 and set an “overweight” rating on the stock in a research report on Thursday, March 12th. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $59.56.

Ultragenyx Pharmaceutical Stock Performance

The firm has a market cap of $2.45 billion, a price-to-earnings ratio of -4.07 and a beta of 0.37. The business’s 50 day moving average price is $24.04 and its 200-day moving average price is $25.02.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported ($1.84) earnings per share for the quarter, missing the consensus estimate of ($1.49) by ($0.35). The business had revenue of $136.00 million for the quarter, compared to analyst estimates of $158.19 million. Ultragenyx Pharmaceutical had a negative return on equity of 1,024.42% and a negative net margin of 91.03%.Ultragenyx Pharmaceutical’s revenue was down 2.2% compared to the same quarter last year. During the same quarter last year, the company earned ($1.57) EPS. On average, analysts forecast that Ultragenyx Pharmaceutical Inc. will post -4.53 earnings per share for the current fiscal year.

Insider Activity

In other Ultragenyx Pharmaceutical news, CFO Howard Horn sold 4,683 shares of the company’s stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $24.90, for a total value of $116,606.70. Following the completion of the transaction, the chief financial officer owned 110,342 shares in the company, valued at approximately $2,747,515.80. This represents a 4.07% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Shehnaaz Suliman sold 5,740 shares of the company’s stock in a transaction dated Monday, May 18th. The stock was sold at an average price of $25.12, for a total transaction of $144,188.80. Following the completion of the transaction, the director owned 27,951 shares of the company’s stock, valued at approximately $702,129.12. This trade represents a 17.04% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 24,002 shares of company stock worth $575,039 in the last quarter. Company insiders own 5.20% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of RARE. Assetmark Inc. boosted its stake in Ultragenyx Pharmaceutical by 1,706.7% during the 3rd quarter. Assetmark Inc. now owns 1,084 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 1,024 shares in the last quarter. Huntington National Bank boosted its stake in Ultragenyx Pharmaceutical by 56.2% during the 3rd quarter. Huntington National Bank now owns 1,092 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 393 shares in the last quarter. Danske Bank A S bought a new position in Ultragenyx Pharmaceutical during the 3rd quarter valued at $39,000. Parallel Advisors LLC boosted its stake in Ultragenyx Pharmaceutical by 778.4% during the 1st quarter. Parallel Advisors LLC now owns 1,625 shares of the biopharmaceutical company’s stock valued at $34,000 after purchasing an additional 1,440 shares in the last quarter. Finally, Smartleaf Asset Management LLC boosted its stake in Ultragenyx Pharmaceutical by 205.4% during the 3rd quarter. Smartleaf Asset Management LLC now owns 1,738 shares of the biopharmaceutical company’s stock valued at $53,000 after purchasing an additional 1,169 shares in the last quarter. Institutional investors own 97.67% of the company’s stock.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.